The National FINRISK Study

https://www.neurodegenerationresearch.eu/survey/the-national-finrisk-study/

Title of the cohort

The National FINRISK Study

Acronym for cohort

Finrisk

Name of Principal Investigator

Title	Research professor, MD, Ph.D
First name	Erkki
Last name	Vartiainen

Address of institution where award is held

Institution	The National Institute for Health and Welfare
Street Address	Mannerheimintie 166
City	Helsinki
Postcode	00330

Country

- Finland

Website

www.thl.fi

Contact email

Funding source

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer’s disease and other dementias
- Parkinson’s disease

When studies on the above condition(s) are expected to become possible

- Already possible

2a. Stated aim of the cohort

Finrisk is a large population survey on risk factors of chronic, noncommunicable diseases. The survey is carried out every five years using independent, random and representative population samples from different parts of Finland.

2b. Features distinguishing this cohort from other population cohorts

3a. i) Number of publications that involve use of cohort to date

437

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)

http://www.ktl.fi/portal/suomi/osastot/eteo/yksikot/kroonisten_tautien_epidemiologian_yksikko/finriski/fir

3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment

Age in years from: 25

To ('until death' if applicable): 74

4b. Study criteria: inclusion criteria

The sample was a random sample of 25-74 year old persons from the Finnish Population Information System, stratified according to sex, 10-year age groups, and the six geographical areas.

4c. Study criteria: exclusion criteria

Moving out from one of the sampling areas, death.

5. Size of the cohort (i.e. number of participants enrolled)

- More than 15,000

6a. Measures used to characterise participants

?

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

- No

7. Study design

- Cross sectional survey

8. Cases matched by

- Other health assessment (specify) / N/A
- no case-control definition

9a. Does the study include a specialised subset of control participants

- No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-1992

10a. ii) Data collection end date

10-04-2007

10a iii) Data collection for this study is

- Data collection ongoing
- Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

- Yes – funding applied for

11. Data collected

- Through links to other records or registers (such as dental records, police records etc). Please specify
- morbidity register, cancer register

12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Language used:
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- Resource has own ethics approval so usually no need for separate external ethics approval

15. Data sharing policy specified as a condition of use

- No requirement to make data publicly available

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

- Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

- Secondary samples: DNA

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

- No